Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Interference of Heparin with Peritoneal Solute Transport

      , ,

      Nephron

      S. Karger AG

      Peritoneal dialysis, Mass transport, Heparin, Gentamycin

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To verify the action of heparin on peritoneal transport, we selected 20 patients on acute peritoneal dialysis and performed two 2-hour cycles with 2,000 cm<sup>3</sup> of a 1.5% solution, adding 2,000 units of heparin to the second cycle. The patients were also randomized into 2 groups: group A, adding 1.5 mg gentamycin/kg to the dialysate of cycle I (without heparin), and group B, adding the same dose of gentamycin to cycle II (with heparin). At the end of each of the two cycles blood and dialysate were drawn for urea, creatinine, glucose, proteins and gentamycin levels, using peritoneal clearances of urea and creatinine, glucose absorption and net protein loss to compare cycle I with cycle II. We found that the peritoneal transport of creatinine and urea was improved (p < 0.02; p < 0.05) and glucose absorption increased (p < 0.01) with heparin, without any significant change in protein loss. Contrary to common belief, heparin in a 1,000-U/1 dose improved the absorption of gentamycin from the dialysate (p < 0.01).

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1985
          1985
          04 December 2008
          : 39
          : 1
          : 47-49
          Affiliations
          Nephrology Department, Hospital Curry Cabral, Lisbon, Portugal
          Article
          183336 Nephron 1985;39:47–49
          10.1159/000183336
          3969190
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Peritoneal dialysis, Mass transport, Heparin, Gentamycin

          Comments

          Comment on this article